Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

1.2K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Mutations01:35

Mutations

37.0K
Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
37.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive map of the regulatory network triggered by MET exon 14 skipping reveals important involvement of the RAS-ERK signaling pathway.

Cell death & disease·2025
Same author

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.

Molecular oncology·2025
Same author

Functional interaction between receptor tyrosine kinase MET and ETS transcription factors promotes prostate cancer progression.

Molecular oncology·2024
Same author

MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.

bioRxiv : the preprint server for biology·2023
Same author

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.

FEBS letters·2023
Same author

Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.

Human mutation·2021

Related Experiment Video

Updated: Jun 28, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

Recording and classifying MET receptor mutations in cancers.

Célia Guérin1, David Tulasne1

  • 1Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 - UMR1277 - Canther - Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France.

Elife
|April 23, 2024
PubMed
Summary

Recent advances in tyrosine kinase inhibitors (TKIs) target MET mutations in non-small cell lung cancer (NSCLC). Understanding MET mutations is key to developing effective cancer treatments and overcoming resistance.

Keywords:
cancercancer biologymutationreceptor tyrosine kinasetargeted therapies

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
10:57

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

10.7K

Related Experiment Videos

Last Updated: Jun 28, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K
Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay
10:57

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

10.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The MET receptor tyrosine kinase (RTK) is frequently deregulated in various cancers, promoting tumor progression.
  • The first MET mutation linked to cancer was identified in hereditary papillary renal cancer (HPRC) in 1997.
  • MET mutations, particularly in the kinase domain, often lead to ligand-independent activation.

Purpose of the Study:

  • To review the characterization of MET mutations in cancer development.
  • To outline the discovery and implications of novel MET mutations, including exon 14 skipping.
  • To discuss the challenges in predicting the transforming activity and TKI sensitivity of newly discovered MET mutations.

Main Methods:

  • Literature review of MET mutations in cancer.
  • Analysis of the impact of MET mutations on receptor activation and cancer progression.
  • Review of therapeutic strategies targeting MET, including tyrosine kinase inhibitors (TKIs).

Main Results:

  • Tyrosine kinase inhibitors (TKIs) targeting MET are approved for advanced non-small cell lung cancer (NSCLC) with specific MET mutations.
  • MET exon 14 skipping mutations, discovered in 2014, represent a distinct class of MET alterations.
  • While MET TKIs show efficacy in NSCLC with MET exon 14 skipping, resistance mechanisms involving new MET mutations have emerged.

Conclusions:

  • The discovery and characterization of MET mutations have been pivotal in advancing cancer therapy.
  • Ongoing research is crucial for understanding novel MET mutations and their response to TKIs.
  • Predicting the transforming potential and TKI sensitivity of MET mutations is essential for personalized cancer treatment strategies.